In vivo assays showed that HCP5 could abrogate the anti-tumor effect of FOLFOX regime, indicating that targeting HCP5 could be an innovative way to higher the efficacy of chemotherapy in GC. This evidence concerns the gene HCP5 and gastric cancer.